Literature DB >> 11181776

Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

D Solomon1, M Schiffman, R Tarone.   

Abstract

BACKGROUND: More than 2 million U.S. women receive an equivocal cervical cytologic diagnosis (atypical squamous cells of undetermined significance [ASCUS]) each year. Effective colposcopy triage strategies are needed to identify the minority of women who have clinically significant disease while avoiding excessive follow-up evaluation for others.
METHODS: The ASCUS/LSIL (i.e., low-grade squamous intraepithelial lesion) Triage Study (ALTS) is a multicenter, randomized trial comparing the sensitivity and specificity of the following three management strategies to detect cervical intraepithelial neoplasia grade 3 (CIN3): 1) immediate colposcopy (considered to be the reference standard), 2) triage to colposcopy based on human papillomavirus (HPV) results from Hybrid Capture 2(TM) (HC 2) and thin-layer cytology results, or 3) triage based on cytology results alone. This article summarizes the cross-sectional enrollment results for 3488 women with a referral diagnosis of ASCUS. All statistical tests are two-sided.
RESULTS: Among participants with ASCUS, the underlying prevalence of histologically confirmed CIN3 was 5.1%. Sensitivity to detect CIN3 or above by testing for cancer-associated HPV DNA was 96.3% (95% confidence interval [CI] = 91.6% to 98.8%), with 56.1% of women referred to colposcopy. Sensitivity of a single repeat cytology specimen with a triage threshold of HSIL or above was 44.1% (95% CI = 35.6% to 52.9%), with 6.9% referred. Sensitivity of a lower cytology triage threshold of ASCUS or above was 85.3% (95% CI = 78.2% to 90.8%), with 58.6% referred.
CONCLUSIONS: HC 2 testing for cancer-associated HPV DNA is a viable option in the management of women with ASCUS. It has greater sensitivity to detect CIN3 or above and specificity comparable to a single additional cytologic test indicating ASCUS or above.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181776     DOI: 10.1093/jnci/93.4.293

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  124 in total

1.  HPV testing for clarifying borderline cervical smear results.

Authors:  M M Manos
Journal:  BMJ       Date:  2001-04-14

2.  Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible.

Authors:  Philip E Castle; Attila T Lorincz; Iwona Mielzynska-Lohnas; David R Scott; Andrew G Glass; Mark E Sherman; John E Schussler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  European consensus on cancer screening should be applied urgently by health ministers.

Authors:  M Arbyn; H Van Oyen; E Lynge; M Mickshe
Journal:  BMJ       Date:  2001-08-18

4.  Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.

Authors:  Philip E Castle; Erin C Gutierrez; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Laurence M Vaughan; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

5.  Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Authors:  Nicole G Campos; Philip E Castle; Mark Schiffman; Jane J Kim
Journal:  Med Decis Making       Date:  2011-12-06       Impact factor: 2.583

6.  Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.

Authors:  Simon Grandjean Lapierre; Philippe Sauthier; Marie-Hélène Mayrand; Simon Dufresne; Patrick Petignat; Diane Provencher; Pierre Drouin; Philippe Gauthier; Marie-Josée Dupuis; Bertrand Michon; Stéphan Ouellet; Rachid Hadjeres; Alex Ferenczy; Eduardo L Franco; François Coutlée
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

7.  Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins.

Authors:  Allison J Berger; Astrid Baege; Tracy Guillemette; James Deeds; Ron Meyer; Gary Disbrow; Richard Schlegel; Robert Schlegel
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

9.  Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions.

Authors:  Eduardo L Franco; Joseph Tota
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

10.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.